Three-year disease-free survival data from NICHE-2 and findings from NICHE-3 add to current knowledge on the benefits of immune checkpoint inhibition in this setting
Positive data presented from the LEAP-012 study for intermediate-stage disease, but it is still unclear how these will influence clinical practice
New study findings support this treatment strategy as a new standard of care for patients with high-risk, locally advanced cervical cancer
The PODIUM-303 study shows practice-changing results for patients with unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.
Patients with homologous-recombination-deficient advanced ovarian cancer alive at 5 years were twice as likely to be progression free with niraparib than placebo, although no long-term overall survival benefit was reported
New data show that it does not increase the risk of breast cancer recurrence or development of secondary breast cancer in women, nor does it carry any health risks for the child
Extensive research identified the deficiency of a highly accurate DNA repair process known as homologous recombination as an ‘Achilles heel’ in cancer, and led to the development of PARP inhibitors as single-agent therapies
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.